Search

Displaying results 1521 - 1530 of 8696 in total
  1. Drug

    Eliglustat

    go.drugbank.com/drugs/DB09039
    ApprovedInvestigational

    [L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease. … [L41404] Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  2. Drug

    Volanesorsen

    go.drugbank.com/drugs/DB15067
    Approved

    [L16621] This drug is not commonly prescribed as it is used as an adjunct to diet in patients at high risk for pancreatitis, who have had inadequate response to triglyceride lowering therapy. … Volanesorsen is an antisense oligonucleotide that binds to apoC-III mRNA to prevent its translation.

  3. Drug

    Tauroursodeoxycholic acid

    go.drugbank.com/drugs/DB08834
    ApprovedInvestigationalWithdrawn

    Tauroursodeoxycholic acid can reduce the absorption of cholesterol in the small intestine, thereby reducing the body's intake of dietary cholesterol and the body cholesterol content.

  4. Drug

    Cetyl alcohol

    go.drugbank.com/drugs/DB09494
    Approved

    It may be contained in cosmetic and personal care products such as shampoos, creams and lotions. … Cetyl alcohol is also listed in the OTC ingredient list as a skin protectant for skin irritations caused by poison ivy, oak, sumac, and insect bites or stings [L1074].

  5. Drug

    Cariprazine

    go.drugbank.com/drugs/DB06016
    ApprovedInvestigational

    Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. … [A247100] It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors.

    Categories: Serotonin Receptor Agonists, Serotonin Receptor Antagonists
  6. Drug

    Tenapanor

    go.drugbank.com/drugs/DB11761
    ApprovedInvestigational

    In October 2023, tenapanor was approved for the treatment of chronic kidney disease.[L48511] … Tenapanor is a novel, small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C).

    Categories: Drugs for Constipation, Cytochrome P-450 Substrates
  7. Drug

    Estradiol

    go.drugbank.com/drugs/DB00783
    ApprovedInvestigationalVet approved

    Because it has a low oral bioavailability on its own, estradiol is commonly formulated with an ester side-chain. … It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes.

    Categories: Hormonal Contraceptives for Systemic Use, P-glycoprotein substrates
  8. Drug

    Sodium phosphate, dibasic

    go.drugbank.com/drugs/DB14502
    ApprovedInvestigational

    Mixtures: Nutriflex Lipid peri Emulsion zur Infusion, Fleet for Children
  9. Drug

    Anbenitamab

    go.drugbank.com/drugs/DB18411
    Investigational

    Synonyms: FC-fusion bispecific antibody targeting extracellular domains II and IV of HER 2 and FC-fusion bispecific IgG1 antibody inhibiting PD-L1 and CTLA-4, IMMUNOGLOBULIN G1 (369-SERINE,371-ALANINE,408-LYSINE,410-VALINE), ANTI-(HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR HER2 DOMAIN IV)(HUMAN-MUS MUSCULUS MONOCLONAL RHUMAB 4D5 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS
  10. Drug

    Mogamulizumab

    go.drugbank.com/drugs/DB12498
    ApprovedInvestigational

    Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of … [L4168] It was approved for the same indications in Canada in June 2022.

    Categories: Chemokine Receptor Type 4 Interaction, Chemokine Receptor Type 4 Interactions